Clinical trial · Observational
SLPI for Prostate Cancer
SLPI: a Novel Biomarker of Prostate Cancer
NCT04854343CI-TRIAL-00058366unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Exploratory study of SLPI expression in human prostate cancer patients This is a no-profit exploratory study about the expression of SLPI in human prostate cancer patients that will enroll about 200 patients admitted for suspect prostate cancer to Careggi University Hospital. We will verify whether an increase SLPI levels in the sera may serve as biomarker of cancer progression.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Prostatic Neoplasm | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Determination of molecular alterations | Diagnostic Test | — | UNRESOLVED |
| Secretory leukocyte protease inhibitor (SLPI) Healthy | Diagnostic Test | — | UNRESOLVED |
| Secretory leukocyte protease inhibitor (SLPI) in prostate cancer | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Case
- description
- 200 patients with a suspicion of prostate cancer
- interventionNames
- Diagnostic Test: Secretory leukocyte protease inhibitor (SLPI) in prostate cancer
- Diagnostic Test: Determination of molecular alterations
- label
- Control A
- description
- (a) 50 patients with benign prostate hyperplasia (BPH)
- interventionNames
- Diagnostic Test: Determination of molecular alterations
- Diagnostic Test: Secretory leukocyte protease inhibitor (SLPI) Healthy
- label
- Control B
- description
- (b) 30 male subjects older than 50 years with neither prostate disease nor any other neoplasia
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with prostate carcinoma. * Patients with Benign Prostatic Hyperplasia. * Male subjects older that 50 years without prostate or neoplastic diseases. Exclusion Criteria: * Male subjects younger that 50 years without prostate disease. * Male subjects with neoplastic diseases either than prostate.
References
Publications (0)
Data not yet available
No reference posted for this study.